Showing 2031-2040 of 8649 results for "".
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care/2481193/Nanodropper launched its "2022 Give the Gift of Vision" program, an effort to donate 1,000 Nanodropper adaptors to at-need patients in the United States and its global nonprofit partners—designed to deliver better access to vision-saving care in low resource settings in
- Santen Filing Accepted by EMA for Review of Application for STN1013001 Cationic Emulsion of Latanoprost 50μg/mL in Glaucomahttps://modernod.com/news/santen-filing-accepted-by-ema-for-review-of-application-for-stn1013001-cationic-emulsion-of-latanoprost-50mgml-in-glaucoma/2481157/Santen Pharmaceutical announced European Medicines Agency (EMA) acceptance for review of a marketing authorization application for the use of STN1013001 for lowering of IOP in open-angle glaucoma and ocular hypertension. STN1013001 is preservative-free latanoprost 50μg/mL p
- Haag-Streit Announces the Winners of the ‘Slit Lamp Imaging Competition 2022’https://modernod.com/news/haag-streit-announces-the-winners-of-the-slit-lamp-imaging-competition-2022/2481154/Haag-Streit has announced the winners of the ‘Haag-Streit Slit Lamp Imaging Competition 2022.' First place has been awarded to Utpal Sarkar from Disha Eye Hospitals Barrackpore in Kolkata, India. His winning image, taken with a Haag-Streit BX 900 slit lamp imaging sy
- Atsena Therapeutics Announces Late-Breaker Presentation at the AAO Annual Meetinghttps://modernod.com/news/atsena-therapeutics-announces-late-breaker-presentation-at-the-aao-annual-meeting/2481107/Atsena Therapeutics announced that data from the phase 1/2 clinical trial of ATSN-101 will be presented in a late breaking developments session during the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO 2022), which is being held Sept
- Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trialhttps://modernod.com/news/nicox-announces-last-patients-complete-final-visit-in-ncx-470-phase-3-mont-blanc-glaucoma-trial/2481100/Nicox announced that the last patients completed their final (3-month) visit in the Mont Blanc phase 3 clinical trial of NCX 470 0.1% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. A total of
- Heru Expands Wearable Platform with Launch of Dark Adaptationhttps://modernod.com/news/heru-expands-wearable-platform-with-launch-of-dark-adaptation-establishing-market-leading-amd-portfolio/2481090/Heru announced the launch of dark adaptation, the newest modality added to its wearable health and wellness platform’s vision screening line-up. Dark adaptation measures the eye’s ability to adjust from light to dark environments. Impaired dark adaptation may be one of the
- Johnson & Johnson Vision Launches Acuvue Oasys Max 1-Dayhttps://modernod.com/news/johnson-johnson-vision-launches-acuvue-oasys-max-1-day/2481083/Johnson & Johnson Vision Care announced the launch of its newest innovation, Acuvue Oasys Max 1-Day contact lenses and Acuvue Oasys Max 1-Day Multifocal contact lenses for presbyopia. The lenses are designed with a combination of new technologies to help meet the needs of digit
- Rayner to Announce Launch of RayPRO+ Digital Health Platform at the ESCRShttps://modernod.com/news/rayner-to-announce-launch-of-raypro-digital-health-platform-at-the-escrs/2481082/Rayner announced the global launch of RayPRO+ at the upcoming ESCRS 2022 congress in Milan. RayPRO is Rayner’s proprietary mobile app and web-based digital platform that proactively collects a blend of patient reported outcomes (PROs) over 3 years. RayPRO+ has the added ability to
- ESCRS Launches New Awards Program to Foster Digital Transformationhttps://modernod.com/news/escrs-launches-new-awards-program-to-foster-digital-transformation/2481078/The European Society of Cataract & Refractive Surgeons (ESCRS) announced the launch of the 2022 ESCRS Digital Research Awards (DRA), an initiative sponsored by the society to support and encourage innovative research that leads to digital transformation in the fields of cataract, re
- Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the UShttps://modernod.com/news/dr-reddys-laboratories-enters-into-a-licensing-agreement-to-obtain-rights-for-the-private-label-version-of-lumify-in-the-us/2481003/Dr. Reddy’s Laboratories, along with its subsidiaries, announced it has entered into a licensing agreement with Princeton, New Jersey-based Slayback Pharma to acquire rights in Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify